Table 2.
The relationship between FUT2 mRNA expression and clinical parameters of patients with lung adenocarcinoma.
| Characteristic | Low Expression of FUT2 | High Expression of FUT2 | p |
|---|---|---|---|
| n | 267 | 268 | |
| T stage, n (%) | 0.001 | ||
| T1 | 101 (19%) | 74 (13.9%) | |
| T2 | 143 (26.9%) | 146 (27.4%) | |
| T3 | 13 (2.4%) | 36 (6.8%) | |
| T4 | 8 (1.5%) | 11 (2.1%) | |
| N stage, n (%) | 0.522 | ||
| N0 | 178 (34.3%) | 170 (32.8%) | |
| N1 | 44 (8.5%) | 51 (9.8%) | |
| N2 | 36 (6.9%) | 38 (7.3%) | |
| N3 | 0 (0%) | 2 (0.4%) | |
| M stage, n (%) | 0.936 | ||
| M0 | 177 (45.9%) | 184 (47.7%) | |
| M1 | 13 (3.4%) | 12 (3.1%) | |
| Pathologic stage, n (%) | 0.159 | ||
| Stage I | 156 (29.6%) | 138 (26.2%) | |
| Stage II | 51 (9.7%) | 72 (13.7%) | |
| Stage III | 39 (7.4%) | 45 (8.5%) | |
| Stage IV | 14 (2.7%) | 12 (2.3%) | |
| Residual tumor, n (%) | 0.839 | ||
| R0 | 179 (48.1%) | 176 (47.3%) | |
| R1 | 5 (1.3%) | 8 (2.2%) | |
| R2 | 2 (0.5%) | 2 (0.5%) |